Integra Therapeutics

top of page

ASGCT 2026: Barcelona based Integra Therapeutics believes its FiCAT gene writing platform can deliver a larger payload capacity and with more precision than with traditional viral vectors

Co-Founder & CEO Avencia Sánchez-Mejías describes the science of how they achieve this. At ASGCT, the company is presenting the second generation of FiCAT, and offers examples of introducing 3 or 4 genes. Coverage brought to you by

Company News

4 hours ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page

ASGCT 2026: Barcelona based Integra Therapeutics believes its FiCAT gene writing platform can deliver a larger payload capacity and with more precision than with traditional viral vectors

Follow BiotechTV

Sponsors

Sponsor Spotlight